Mahamaya Lifesciences Limited (BOM:544611)
India
· Delayed Price · Currency is INR 160.55
-8.45 (-5.00%)
At close: Mar 9, 2026
Mahamaya Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| Operating Revenue | 2,810 | 2,641 | 1,616 | 1,371 | 899.13 |
| Other Revenue | 0.87 | 0.87 | - | 0.45 | 0.05 |
| Revenue | 2,811 | 2,642 | 1,616 | 1,371 | 899.19 |
| Revenue Growth (YoY) | - | 63.54% | 17.83% | 52.50% | - |
| Cost of Revenue | 2,394 | 2,267 | 1,391 | 1,184 | 752.95 |
| Gross Profit | 417.03 | 374.97 | 224.48 | 186.77 | 146.24 |
| Selling, General & Admin | 86.51 | 78.2 | 54.06 | 50.79 | 55.4 |
| Other Operating Expenses | 63.42 | 49.54 | 36.39 | 38.95 | 26.62 |
| Operating Expenses | 170.89 | 145.46 | 104.51 | 102.46 | 91.62 |
| Operating Income | 246.14 | 229.51 | 119.96 | 84.31 | 54.62 |
| Interest Expense | -58.16 | -55.12 | -46.04 | -26.33 | -15.8 |
| Interest & Investment Income | 2.66 | 2.66 | 3.22 | 0.78 | 0.33 |
| Currency Exchange Gain (Loss) | 9.1 | 9.1 | 4.56 | -5.88 | 0.1 |
| Other Non Operating Income (Expenses) | -11.91 | -12.72 | -9.18 | -2.13 | -2.03 |
| EBT Excluding Unusual Items | 187.83 | 173.43 | 72.52 | 50.76 | 37.21 |
| Gain (Loss) on Sale of Assets | 0.19 | 0.19 | 0.18 | 0.21 | - |
| Other Unusual Items | -0.03 | -1.1 | 1.58 | - | - |
| Pretax Income | 187.99 | 172.52 | 74.28 | 50.96 | 37.21 |
| Income Tax Expense | 48.65 | 44.4 | 20.52 | 13.46 | 9.98 |
| Net Income | 139.34 | 128.12 | 53.76 | 37.51 | 27.23 |
| Net Income to Common | 139.34 | 128.12 | 53.76 | 37.51 | 27.23 |
| Net Income Growth | - | 138.31% | 43.34% | 37.72% | - |
| Shares Outstanding (Basic) | 18 | 17 | 14 | 14 | 14 |
| Shares Outstanding (Diluted) | 18 | 17 | 14 | 14 | 14 |
| Shares Change (YoY) | - | 23.62% | - | - | - |
| EPS (Basic) | 7.85 | 7.55 | 3.91 | 2.73 | 1.98 |
| EPS (Diluted) | 7.85 | 7.55 | 3.91 | 2.73 | 1.98 |
| EPS Growth | - | 92.78% | 43.36% | 37.88% | - |
| Free Cash Flow | -129 | -83.49 | -249.73 | -17.7 | -11.07 |
| Free Cash Flow Per Share | -7.26 | -4.92 | -18.18 | -1.29 | -0.81 |
| Gross Margin | 14.84% | 14.19% | 13.89% | 13.62% | 16.26% |
| Operating Margin | 8.76% | 8.69% | 7.42% | 6.15% | 6.08% |
| Profit Margin | 4.96% | 4.85% | 3.33% | 2.73% | 3.03% |
| Free Cash Flow Margin | -4.59% | -3.16% | -15.46% | -1.29% | -1.23% |
| EBITDA | 262.29 | 242.43 | 129.58 | 92.78 | 62.85 |
| EBITDA Margin | 9.33% | 9.18% | 8.02% | 6.77% | 6.99% |
| D&A For EBITDA | 16.15 | 12.92 | 9.62 | 8.46 | 8.22 |
| EBIT | 246.14 | 229.51 | 119.96 | 84.31 | 54.62 |
| EBIT Margin | 8.76% | 8.69% | 7.42% | 6.15% | 6.08% |
| Effective Tax Rate | 25.88% | 25.74% | 27.63% | 26.40% | 26.82% |
| Revenue as Reported | 2,844 | 2,672 | 1,628 | 1,374 | 901.56 |
Source: S&P Capital IQ. Standard template. Financial Sources.